Used in clinical research for the treatment of advanced solid tumors, particularly in studies involving immune-oncology. It functions as a selective adenosine A2A receptor antagonist, helping to enhance anti-tumor immune responses by blocking immunosuppressive signals in the tumor microenvironment. Currently investigated in phase 1 and phase 2 trials, often in combination with other immunotherapies like PD-1 inhibitors, to improve outcomes in cancers such as non-small cell lung cancer and melanoma. Its development aims to overcome resistance to existing immunotherapies and boost T-cell activation against tumors.